RxDoctor Payments Data

Kaitlin Beadles, PA

Physician Assistant · Phoenix, AZNPI 1174141238

Payments from drug & device makers

$8,101in general payments, 2019–2025

Across 331 payments — averaging $24.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$817
  • Gilead$522
  • Sanofi$518
  • Johnson & Johnson$506
  • Ardelyx, Inc.$505
  • plus $3K from 31 others

What the payments were for

  • Food & beverage$8,101100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,101 in reported general payments places this provider in the 95th percentile of 2,888 physician assistant providers in Arizona.

See all physician assistant providers in Arizona

Medicare billing

Part B allowed, 2024
$36,277
Medicare patients
240
Services billed
375

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase21$55,139
LinzessLinaclotide20$13,073
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag48$5,937
Dexlansoprazole DrDexlansoprazole13$5,913
Sucralfate33$4,471
ClenpiqSod Picosulf/Mag Ox/Citric Ac22$3,821
Colestipol Hcl64$2,813
Pantoprazole Sodium164$2,250
Famotidine99$1,854
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates24$1,480
Omeprazole75$1,109
Dicyclomine Hcl35$611
Metronidazole44$430
Esomeprazole Magnesium12$319
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl15$222

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,952$68,21241 claims
Braintree Laboratories, Inc.Suflave$29$5,93748 claims
Ferring Pharmaceuticals Inc.Clenpiq$210$3,82122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,888 physician assistant providers in Arizona.

Other physician assistant in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →